Jörn Aldag is CEO of gene therapy company uniQure N.V., Netherlands, which received the first approval of a gene therapy product by any Western regulatory agency and recently listed the company on NASDAQ. He is Chairman of alternative antibody company Molecular Partners AG, Switzerland. He previously transformed Evotec AG from being a provider of ultra-high throughput screening equipment to being a leading CRO for small molecule research, listed the company at the Frankfurt Stock Exchange and NASDAQ, and managed the acquisition of LSE-listed Oxford Asymmetry and NASDAQ-listed Renovis Inc. He holds business degrees from the European Business School and the Harvard Business School.
Philip Astley-Sparke has served as the president of our United Stated operations since January 2013. Mr. Astley-Sparke has been a venture partner at Forbion Capital Partners, a venture capital fund, since May 2012. He served as vice president and general manager at Amgen, Inc., a biopharmaceutical company, until December 2011, following Amgen’s acquisition of BioVex Group, Inc., a biotechnology company, in March 2011. Mr. Astley-Sparke had been president and chief executive officer of BioVex Group since 2007, which he joined in 2000, and previously served in roles of President, COO and CFO where he oversaw the company’s relocation to the U.S. where he grew operations from scratch, including overseeing the construction of and commercial-grade manufacturing facility. Prior to Biovex, Mr. Astley-Sparke was a healthcare investment banker from Chase H+Q/Robert Fleming. He qualified as a chartered accountant with Arthur Andersen in London and holds a bachelor’s degree in cellular pathology and molecular pathology from Bristol University in the United Kingdom. He also serves as chairman of the board of Oxyrane, a biotechnology company.
Dr. Petry joined uniQure’s predecessor company AMT in May 2007 as Director of Research and Development. He has worked in the area of gene therapy for more than 15 years and has extensive experience in pharmaceutical research. After his PhD, he built up a career in academic research and subsequently in the international biopharmaceutical industry. For the last 10 years, in addition to uniQure, he has worked at Jenapharm GmbH (Germany), and Berlex Biosciences (US) in different functions with increasing managerial and leadership responsibility.
Dr. Preusting joined uniQure’s predecessor company AMT in August 2006 and is responsible for Business Development. He holds a PhD in Biochemistry and an MBA from Rotterdam School of Management. He has 20 years of experience in product development and manufacturing using fermentation and cell culture techniques. Prior to uniQure, he was at Solvay Pharmaceuticals, DSM and Gist-brocades. Hans Preusting holds two patents and has published over 20 scientific articles.
Chief Commercial Officer Hans Christian Rohde (M.Sc., MBA) has almost 25 years experience in commercial roles at leading biotechnology and pharmaceutical companies. From 2007 until 2012 he was Chief Commercial Officer at Basilea Pharmaceutica, and member of the company’s executive management committee with responsibility for global commercial operations, marketing, supply chain, medical affairs, pricing and market access.Prior to Basilea Pharmaceutica, Mr. Rohde was Corporate Vice President, Head of Global Therapeutic Areas Reproductive Health and Endocrinology at Merck-Serono from 2003 until 2007. Before this he was responsible for international marketing and global market development at Biogen Idec. From 1992 until 2000, Mr Rohde held positions of increasing commercial responsibility at Novo Nordisk. Mr. Rohde started his career at Laboratoires Syntex.
Dr. Meyer joined uniQure as Chief Medical Officer in 2013. He has more than 13 years of clinical research experience with both biotechnology companies and large pharmas and particular expertise in the development of treatments for rare diseases. Dr. Meyer joined uniQure from Cardoz AB where he spent three years as Chief Medical Officer. From 2006 to 2010, Dr. Meyer held leadership positions in clinical development at Symphogen A/S, where he was Senior Vice President for Medical Affairs and Vice President, Clinical Development. Prior to Symphogen, he played an important role in clinical development at Zymenex A/S and spent five years in clinical development at Novo Nordisk A/S. Dr. Meyer received both his M.D. and Ph.D. degrees from the University of Copenhagen, Denmark.
Eric Goossens joined uniQure as Chief Operating Officer in 2014 from Dätwyler Pharma Packaging Belgium N.V. where he spent three years as Site Director responsible for the Belgium and Germany sites. Prior to this, he held leadership positions in operations at Sekisui S-LEC Europe B.V., where he was responsible for the Film Plant Operations and Supply Chain. From 2002 to 2006 he was Project Manager and Director Production Operations at Centocor B.V. where he played an important role in a major site expansion, building a new biopharmaceutical production facility. Mr. Goossens holds a Master’s degree in Chemistry from the University of Utrecht, the Netherlands, as well as a Master of Engineering from the University of Twente, the Netherlands. His educational background includes international executive leadership programs at the business schools of INSEAD and IMD.
Mrs. Konforty joined uniQure as SVP Corporate Services beginning 2014. She has more than 15 years of experience in leading Service Strategy for both internal and external customers in global public corporations, with strong culture diversity and changing economic climates in Europe and the US. Mrs. Konforty joined uniQure from eBay Classifieds Group where she led both HR and Operations in the NL branch. Prior to eBay, Mrs. Konforty worked in NetApp EMEA headquarters, HR consultancy group and startups in different growth phase. She graduated Psychology and Communication in Haifa University and has a pending Master in Labor Studies from Tel Aviv University, Israel.